5/6 Nephrectomy-induced Rat CKD Model

Anti-Tumor Drug Efficacy Evaluation
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Autoimmune Disease Efficacy Evaluation
Autoimmune Nephropathy Models and Efficacy ServicesAsthma Models and Efficacy ServicesSystemic Lupus Erythematosus (SLE) Models and Efficacy ServicesSjögren's Syndrome Models and Efficacy ServicesNeuroimmune Diseases Models and Efficacy ServicesAutoimmune Dermatoses Models and Efficacy ServicesInflammatory Bowel Disease (IBD) Models and Efficacy ServicesRheumatoid Arthritis (RA) Models and Efficacy ServicesImmune Reconstitution Autoimmune Disease Models and Efficacy Services
Metabolic Disease Efficacy Evaluation
Obesity Models and Efficacy ServicesType II Diabetes Models and Efficacy ServiceType I Diabetes Models and Efficacy ServicesAndrogenetic Alopecia (AGA) Models and Efficacy ServicesMASH Models and Efficacy ServicesChronic Liver Fibrosis Models and Efficacy ServicesAcute Liver Injury Models and Efficacy ServicesCholestasis Models and Efficacy ServicesAlcohol-related Liver Disease (ALD) Models and Efficacy ServicesChronic Kindey Disease (CKD) Models and Efficacy ServicesActue Kindey Disease (AKD) Models and Efficacy ServicesDiabetes Nephropathy (Diabetic Kidney Disease) Models and Efficacy ServicesSarcopenia Models and Efficacy ServicesGout/Hyperuricemia Models and Efficacy ServicesFemale Reproduction Models and Efficacy Services
Neurological Disease Efficacy Evaluation
Behavioral AnalysisIn Vivo Drug Efficacy EvaluationDelivering Therapeutics Across the Blood-Brain Barrier (BBB)Parkinson’s Disease Rat Model
Cardiovascular Diseases Efficacy Evaluation
Heart Failure Models and Efficacy ServicesHypertension Models and Efficacy ServicesAtherosclerosis Models and Efficacy ServicesAdvanced Cardiovascular and Metabolic Complication Models and Efficacy ServicesHyperlipidemia Models and Efficacy ServicesHypertropic Cardiomyopathy Models and Efficacy ServicesStroke Models and Efficacy ServicesThrombosis Models and Efficacy Services
Infectious Disease Efficacy Evaluation
About Our Biosafety LaboratoryIn vitro Drug Efficacy EvaluationIn vivo Drug Dfficacy Evaluation
Respiratory Disease Efficacy Evaluation
Acute Lung Injury (ALI) ModelsIdiopathic Pulmonary Fibrosis (IPF) ModelsChronic Obstructive Pulmonary Disease (COPD) ModelsBronchiectasis ModelsPulmonary Function Test
Disease Rat Models
60% HFD Induced DIO Rat ModelsHFHSD+STZ Induced Type II Diabetes Model in SD Rat45％HFHS+STZ Induced Type I Diabetes Models in SD RatCDAHFD-induced Rat MASH ModelCCL4-induced Chronic Liver Fibrosis Models in SD Rat5/6 Nephrectomy-induced Rat CKD ModelAdenine-induced Rat CKD ModelOVX-induced Rat Osteoporosis Model2K1C-induced Hypertension Model in SD RatMCAO-induced CIS Model in SD Rat
Bioanalytical Services
Phenotyping Services
Oncology PlatformMetabolism PlatformEfficacy and Pathology Platform
Non-GLP Toxicity Assessment Services
Cell Therapy & Gene Therapy Efficacy Evaluation

Chronic kidney failure, also known as chronic kidney disease (CKD), is a progressive and irreversible deterioration of kidney function over months or years. It results in the kidneys' inability to effectively filter waste, regulate electrolytes, maintain fluid balance, and produce essential hormones. At GemPharmatech, we offer validated models of CKD to meet your research needs.


5/6 nephrectomy-induced rat CKD model

The 5/6 nephrectomy model is a widely used experimental method to induce chronic kidney failure (CKD) in rats. By surgically removing 5/6 of the kidney mass, the remaining renal tissue undergoes hyperfiltration injury, leading to progressive glomerulosclerosis tubulointerstitial fibrosis, and renal dysfunction, mimicking human CKD progression.

 

11.png

Fig.1 Overview of pharmacodynamic evaluation on 5/6 nephrectomy-induced rat CKD model

 

 22.png

Fig.2 Body weight, urine biochemistry and blood pressure of 5/6 nephrectomy-induced rat CKD model


Body weight curve of 5/6 nephrectomy-induced rat CKD model is shown in Fig. 2A. The 24h-urine volume, urine MALB and CREA level were significantly higher in 5/6 nephrectomy-induced CKD rats compared to the control group(Fig. 2B-D). The SBP, DBP and MBP were significantly higher in 5/6 nephrectomy-induced CKD rats compared to the control group at W6(Fig. 2E). Data were presented by mean ± SEM, n=4-8. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001.

 

33.png

Fig.3 Kidney weight of 5/6 nephrectomy-induced rat CKD model


There is no significant difference in kidney weight between 5/6 nephrectomy-induced CKD rats compared to the control group. Data were presented by mean ± SEM, n=3. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001.

 

44.png

Fig.4 Histological observation of 5/6 nephrectomy-induced rat CKD model


Histopathological analysis of the rat kidney demonstrated marked renal injury, characterized by diffuse inflammatory infiltrates, pronounced tubular dilation and tubular necrosis, extensive interstitial fibrosis, and irregular GBM thickening in 5/6 nephrectomy-induced CKD rats at W9.

Data request in progress, please wait…